[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613780":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Joslin Diabetes Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants will be instructed to drink two HP-DSF shakes","EXPERIMENTAL",null,[13],"Dietary Supplement: protein supplement",{"label":15,"type":16,"description":11,"interventionNames":11},"Participants in this control group will follow the regular standard of diabetes care","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DIETARY_SUPPLEMENT","protein supplement","HP-DSF shakes provided by Abbott Nutrition",[9],[24],{"name":25,"affiliation":5,"role":26},"Osama Hamdy, MD, PhD","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Marwa Al-Badri, MD","CONTACT","6179758258","marwa.albadri@joslin.harvard.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-71.05977,42.35843,{"lat":45,"lon":44},[48,49,51],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"name":50,"role":26,"phone":11,"phoneExt":11,"email":11},"Osama Hamdy, MD., PhD",{"name":52,"role":53,"phone":11,"phoneExt":11,"email":11},"Adham Mottalib, MD","SUB_INVESTIGATOR",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[57],{"name":58,"class":59},"Abbott","INDUSTRY","100613780","nutrition-effect-of-a-high-protein-diabetes-formula-on-body-composition-in-type-2-diabetes-patients-treated-with-incretin-mimetics-100613780",false,"NCT07271043","Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics","Evaluating the Efficacy of High-Protein Diabetes Specific Formula (HP-DSF) on Body Composition in Overweight\u002FObese Patients With Type 2 Diabetes Treated With Incretin Mimetic Drugs","Inclusion Criteria:\n\n1. Subject is between 18-75 years of age\n2. Subject was diagnosed with type 2 diabetes at least 3 months prior to screening\n3. Subject is about to start treatment with an IMD, a GLP-1 receptor agonist (RA) alone or a dual GLP-1\u002FGIP RA. These treatments include either semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), or dulaglutide (Trulicity®)\n4. Body mass index (BMI) is ≥ 25 kg\u002Fm2\n\nExclusion Criteria:\n\n1. Subject has type 1 diabetes mellitus\n2. Subject with estimated glomerular filtration rate \\\u003C60 milliliters\u002Fminute\u002F1.73 m²,\n3. Urine albumin-to-creatinine ratio (UACR) of 300 mg\u002Fg or higher\n4. History of acute kidney injury (AKI) during the 6 months prior to screening g.\n5. Intolerance or allergy to HP-DSF shake or to any of its ingredients\n6. Women who are pregnant or lactating or expect to be pregnant or lactating during the study period.\n7. Women of childbearing potential who are not using highly effective contraceptive methods.\n\n   \\-","ALL","18 Years","75 Years",{"count":71,"type":72},60,"ESTIMATED","INTERVENTIONAL",[75],"NA","A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.",[78],"Type 2 Diabetes","2026-05-27",{"date":81,"type":82},"2026-05-29","ACTUAL",{"date":84,"type":82},"2026-01-01",{"date":86,"type":72},"2026-12-01",{"name":5,"class":6},1]